Acute Agitation And Aggression Treatment Industry Valued at $7.77 Billion by 2029 With CAGR of 6.4% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Acute Agitation And Aggression Treatment Market From 2025 To 2029?
The market size for treating acute agitation and aggression has seen robust growth in the past few years. The market is projected to expand from $5.72 billion in 2024 to $6.05 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%. The impressive growth experienced in the past is due to advancements in pharmacology, an increase in clinical research, regulatory approvals, a rise in the number of acute agitation and aggression cases, and enhanced recognition of mental health issues.
What Is the Projected Market Size of the Acute Agitation And Aggression Treatment Market?
The market for treating severe agitation and aggression is predicted to experience significant expansion in the coming years. By 2029, it is projected to reach a value of $7.77 billion, with a compound annual growth rate (CAGR) of 6.4%. This projected growth during the forecast period is primarily due to various factors such as the increasing aging population, the expansion of healthcare infrastructure, increased investment in the pharmaceutical industry, the growth of home care, and increased disposable income. Furthermore, the major trends anticipated during this forecast period include non-drug therapies, precision medicine, usage of artificial intelligence, and predictive analytics, community support, and collaboration within the industry.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13078&type=smp
Who are the Major Competitors in the Acute Agitation And Aggression Treatment Market Outlook?
Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc
What Is Fueling Growth in the Acute Agitation And Aggression Treatment Market?
The escalating prevalence of dementia is predicted to fuel the expansion of the acute agitation and aggression treatment market in the near future. Dementia involves conditions typified by memory impairment, diminished cognitive abilities, and a compromised ability to carry out daily tasks. One of the frequently seen symptoms in dementia sufferers is agitation, which is displayed through signs such as restlessness, repeated actions or recurrent hand movements. In such circumstances, acute agitation and aggression treatments significantly contribute towards managing dementia, as they minimize the chances of detrimental symptoms, enhance the patient’s life quality, and control the root cause of the agitation. For example, as per the Australian Institute of Health and Welfare, a governmental agency based in Australia, projected in 2022 that approximately 401,300 Australians would be diagnosed with dementia, a figure that is predicted to double to 849,300 by 2058 as stated in February 2023. Therefore, the escalating prevalence of dementia is significantly contributing to the expansion of the acute agitation and aggression treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13078&type=smp
Which Acute Agitation And Aggression Treatment Market Segments Are Growing the Fastest?
The acute agitation and aggression treatment market covered in this report is segmented –
1) By Treatment Approach: Behavioral Approaches, Environmental Interventions, Pharmacologic Approaches
2) By Drug Class: Anti-Psychotics, Benzodiazepines, Other Drug Classes
3) By Route of Administration: Oral, Intramuscular, Other Routes of Administrations
4) By Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-Induced Agitation And Aggression, Alcohol Withdrawal, Other Indications
5) By End User: Hospitals And Ambulatory Surgical Centers, Psychiatric Care Facilities, Other End Users
Subsegments:
1) By Box Style: Standard Box Action Cameras, Modular Box Action Cameras
2) By Cube Style: Compact Cube Action Cameras, Cube Cameras with Integrated Mounts
3) By Bullet Style: Long, Cylindrical Action Cameras, Mountable Bullet Cameras
4) By Periscope & 360°: 360-Degree Cameras, Periscope Cameras
5) By Other Types: Wearable Action Cameras, Drone Action Cameras, Specialty Action Cameras
Which Industry Trends Are Shaping the Future of the Acute Agitation And Aggression Treatment Market?
Key players in the acute agitation and aggression treatment market are introducing novel products and securing approvals, for instance, IGALMI (dexmedetomidine), offering a fresh treatment alternative for those suffering from agitation linked to schizophrenia or bipolar disorder. IGALMI (dexmedetomidine) is a sublingual film for the treatment of acute agitation related to schizophrenia or bipolar I or II disorder in adults. For example, BioXcel Therapeutics Inc., an American biopharmaceutical firm, was granted IGALMI (dexmedetomidine) approval by the Food and Drug Administration in April 2022. The drug acts rapidly, taking effect in just a few minutes. Despite being a short-acting medication, its effects can last up to 2 hours. It has the potential to considerably enhance current treatments for severe or life-threatening situations.
Access The Full Report Here:
Which Countries Are Leading the Acute Agitation And Aggression Treatment Market?
The countries covered in the acute agitation and aggression treatment market market report include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13078
This Report Delivers Insight On:
1. How big is the acute agitation and aggression treatment market, and how is it changing globally?
2. Who are the major companies in the acute agitation and aggression treatment market, and how are they performing?
3. What are the key opportunities and risks in the acute agitation and aggression treatment market right now?
4. Which products or customer segments are growing the most in the acute agitation and aggression treatment market?
5. What factors are helping or slowing down the growth of the acute agitation and aggression treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
